Leukemic cells from patients with B-cell chronic lymphocytic leukemia (B-CLL) express tumor necrosis factor (TNF) and interleukin-2 (IL-2) receptors, but only a low proliferative response can be elicited in vitro by TNFa and IL-2. To investigate the functional properties of IL-2 and TNFa on leukemic B cells, we evaluated (1) the regulation of expression of TNF receptors (TNF-R) and IL-2 receptors on leukemic B cells after culture with TNFa and IL-2; (2) the effect of the combination of TNFa and 11-2 in a proliferative in vitro assay; and (3) the expression and regulation by these cytokines of receptors for hematopoietic factors, including IL-3, granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Flow cytometry analysis showed that freshly isolated leukemic cells from B-CLL patients bear the 75-kD TNF-R and the 55-kD IL-2R; TNFa was able t o upregulate the 55-kD IL-2R but not the 75-kD EUKEMIC CELLS from patients with type-B chronic lymphocytic leukemia (B-CLL) express cytokine receptors, including interleukin-2 and tumor necrosis factor receptors (IL-2R and TNF-R)."4 In particular, the 75-kD TNF-R and the low-affinity IL-2R (55-kD IL-2R) have been found on freshly isolated and cultured leukemic B cells. Recently, IL-2R and TNF-R have been observed to be related. In particular, IL-2 upregulates the expression of TNF-R on in vitro cultured peripheral blood T cells:-7 and TNFa upregulates the expression of IL-2R,".' thus indicating that the regulation of these receptors (both IL-2R and TNF-R) and the effects of relevant cytokines are likely to be closely related on T cells. Furthermore, besides the well-known proliferative effect displayed in response to IL-2 by different cell types, this molecule is able to regulate the production of different cytokines. In particular, the separate triggering of the 55-kD IL-2R (CD25) or the 75-kD IL-2R (CD122) results in the production of interferon-y or granulocyte-macrophage colony-stimulating factor (GM-CSF) in T and natural killer (NK) cells,839 thus pointing to the role of IL-2R in the transmission of other functional properties that are unrelated to the proliferation effect. Although TNFa and IL-2 are able to induce a slight proliferative effect on leukemic cells from B-CLL the relationships between IL-2R and TNF-R and between these two receptorial structures and other cytokine receptors in response to their specific cytokines have not been investigated in this disorder.
EUKEMIC CELLS from patients with type-B chronic lymphocytic leukemia (B-CLL) express cytokine receptors, including interleukin-2 and tumor necrosis factor receptors (IL-2R and TNF-R)."4 In particular, the 75-kD TNF-R and the low-affinity IL-2R (55-kD IL-2R) have been found on freshly isolated and cultured leukemic B cells. Recently, IL-2R and TNF-R have been observed to be related. In particular, IL-2 upregulates the expression of TNF-R on in vitro cultured peripheral blood T cells:-7 and TNFa upregulates the expression of IL-2R,".' thus indicating that the regulation of these receptors (both IL-2R and TNF-R) and the effects of relevant cytokines are likely to be closely related on T cells. Furthermore, besides the well-known proliferative effect displayed in response to IL-2 by different cell types, this molecule is able to regulate the production of different cytokines. In particular, the separate triggering of the 55-kD IL-2R (CD25) or the 75-kD IL-2R (CD122) results in the production of interferon-y or granulocyte-macrophage colony-stimulating factor (GM-CSF) in T and natural killer (NK) cells,839 thus pointing to the role of IL-2R in the transmission of other functional properties that are unrelated to the proliferation effect. Although TNFa and IL-2 are able to induce a slight proliferative effect on leukemic cells from B-CLL the relationships between IL-2R and TNF-R and between these two receptorial structures and other cytokine receptors in response to their specific cytokines have not been investigated in this disorder.
Other cytokines, including colony-stimulating factors (CSFs) and, in particular, IL-3 have been reported to act as growth factors for normal B cells,14 inducing the in vitro proliferation and differentiation of plasma cell precursor^^^ and leukemic B-cell precursors.'6 CSFs represent a family of glycoproteins initially identified by their capacity to support the proliferation of hematopoietic progenitor cells in vitro.I7 These factors are also capable of functionally activating differentiated cells in a lineage-specific fashion. Acti more, neoplastic B cells are able to synthesize GM-CSF?3 Little is known on the role of these molecules and their own receptors on neoplastic B lymphocytes of patients with B-CLL.
In a series of B-CLL patients, we investigated the relationship between TNF-R and IL-2R and the expression of receptors for CSFs, including IL-3, granulocyte colony-stimulating factor (G-CSF), and GM-CSF, after in vitro culture of leukemic B cells in the presence of TNFa and IL-2. We observed that TNFa upregulates the expression of IL-2R and that these two cytokines display a synergistic proliferative effect when added together in vitro to leukemic cells. Leukemic B cells also express IL-3, G-CSF, and GM-CSF receptors; these receptors are upregulated by IL-2 but not by TNFa. Despite the expression of these receptors, CSFs exhibited no proliferative effect on CLL leukemic B cells, with the only exception being GM-CSF.
at the time of diagnosis and had never received any treatment before entering this study. The diagnosis was established on the basis of typical clinical, morphologic, histologic, and immunologic features, as previously described.' B-CLL patients were graded according to the Rai staging systemz4 as follows: stage 0 (3 cases), stage I ( 5 cases), stage I1 (3 cases), and stage I11 (1 case). The total lymphocyte count ranged from 15,200 to 61,250lyL.
Cell separation and B-cell enrichment.
Peripheral blood lymphocytes (PBL) from patients under study were obtained from freshly heparinized blood by centrifugation on Ficoll-Hypaque gradient. The cells were then washed three times with phosphate-buffered saline (PBS) and were resuspended in RPMI 1640 medium (GIBCO, Paisley, UK).
The samples were enriched for B lymphocytes using a modification of the method previously described. After removal of E-rosetting cells by the neuraminidase-(Sigma Chemical CO, St Louis, MO) treated sheep red blood cell rosetting technique, the cell suspension was depleted of adherent cells by incubation for 45 minutes in plastic Petri dishes at 37°C in an atmosphere of 95% air and 5% COz.
Following the method of Lea et cells were further purified by removing CD3' and CD56' lymphocytes using magnetic microspheres coated with antimouse IgG (Dynebeads, Dynal, Norway), as previously described in detail.*' Briefly, after incubation (45 minutes at 4°C) of the cell suspension obtained as above with CD3 (OKT3; Ortho, Raritan, NJ) and CD56 (Leu 19; Becton Dickinson, Sunnyvale, CA) monoclonal antibodies (MoAbs), 40 X IO6 beads were incubated with 10 X 1 O6 cells/mL for 30 minutes at 4°C under continuous slow rotation. The CD3' and CD56' cells rosetting with antibody-coated beads were then isolated and removed applying a magnetic system on the outer wall of the test tubes for 2 minutes. After this multistep negative selection procedure, more than 97% of the cells were viable as judged by trypan blue exclusion test and were found to be positive with CD19 and CD5 MoAbs. Normal B cells were obtained from the spleen of 4 subjects who underwent posttraumatic splenectomy. After mechanic disruption of the spleen, cell suspensions were centrifuged on Ficoll-Hypaque gradient and B lymphocytes were further enriched in the same way as reported for leukemic B cells.
Reagents. TNFa with a specific activity of 8.74 X IOh Ulmg protein was kindly provided by Dr V. Schwendemann and Dr E. Schlick (Knoll, Germany). Recombinant IL-2 with a specific activity of 5.8 X lo6 Ulmg was obtained from Biogen (Cambridge, MA).
GM-CSF, G-CSF, and IL-3 (with specific activities of 1 X 10' U/ m L , 2 x 10' UlmL, and 2 to 5 X lo7 U/mL, respectively) were purchased from Genzyme Corp (Cambridge, MA). Phycoerythrin (PE)-conjugated IL-2, TNFa, GM-CSF, IL-3, and G-CSF were purchased from R & D Systems (Minneapolis, MN). The MoAbs utr-1 and htr-9 were kindly provided by Dr M. Brockhaus (Basel, Switzerland). utr-l and htr-9 MoAbs recognize the 75-kD and 55-kD TNF-Rs, respecti~ely.~~ Anti-CD25 (anti-Tac) MoAb, which recognizes the 55-kD IL-2-R and blocks IL-2 binding to this subunit, was a gift from Dr T. Uchiyama (Kyoto, Japan)"; TU27 and Mikpl MoAbs were gifts from Dr K. Sugamura (Senday, Japan), J. Hamuro (Kawasaki, Japan), and Dr M. Tsudo (Tokyo, Japan),29,3" respectively; they recognize the 75-kD chain of IL-2R (CD122). The following MoAbs that recognize CSF receptors were used: anti-IL-3R (Y chain (S12; Santa Cruz Biotechnology Inc. Santa Cruz, CA) recognizes the 70-kD IL-3R (Y chain and anti-GM-CSFR a chain MoAbs (S20 and S50; Santa Cruz Biotechnology) that recognize the 80-kD human GM-CSFR.
Flow cytometric analysis of TNF receptors by MoAbs and cytokine binding. The analysis of the expression of cytokine receptors was performed with MoAbs recognizing TNF receptors (utr-l and htr-9 for TNF-R1 and TNF-R2), IL-2 receptors (anti-Tac and Mikpl for 55-kD and 75-kD IL-~Rs), and CSF receptors (S 12 for IL-3 receptor, S20 and S50 for GM-CSF receptor) and by using PE-conjugated cytokines (PE-TNFa, PE-IL-2, PE-GM-CSF, PE-G-CSF, and PE-1L-3), as previously described in detail.' The analysis of the expression of the above-mentioned receptors was performed on freshly isolated normal and leukemic B cells and on neoplastic B lymphocytes cultured for 3 days in medium alone supplemented with 10% fetal calf serum (FCS) or in the presence of several cytokines, including TNFa (100 U/mL) and IL-2 (1,000 UlmL). Before staining. the cells were washed in 40 mmoK citrate containing 140 mmol/L NaCI, pH 4, to remove possible bound TNFa. After this procedure, the viability of cells was higher than 90%, as evaluated with the trypan blue exclusion test. The cells were resuspended in PBS and were stained for indirect immunofluorescent analysis by incubating the cells with utr-l, htr-9, anti-IL-3, and anti-GM-CSF receptor MoAbs followed by an incubation with F(ab)* goat antimouse (Technogenetics, Turin, Italy), as previously described.' Ten thousand cells bearing the typical lymphocyte scatter were scored. To analyze receptor expression with PE-conjugated cytokines, IO* cells were incubated with 10 yL of PE-conjugated cytokine ( I 0 yg/mL) for 60 minutes on ice. Cells were then washed twice and resuspended in 0.2 mL of PBS for flow cytometric analysis. As control for the fluorescence-activated cell sorter (FACS) analysis, cells were incubated with avidin PE. The lymphocytes were analyzed as indicated below. In the analysis of TNF, IL-2, IL-3, and GM-CSF receptors, blocking experiments were performed by pretreating the cells for I hour at 4°C with the following antibodies: 20 yg/mL of utr-1 MoAb, 20 yg/mL of htr-9 MoAb, 20 yg/mL of anti-CD25 MoAb, 100 ygl mL of TU27 MoAb, and I O yg/mL of anti-IL-3 or anti-GM-CSF receptor MoAbs. After this incubation, the cells were washed twice and successively incubated with PE-TNFa. PE-IL-2, PE-IL-3, and PE-GM-CSF, as reported above. For flow cytometric analysis, IO4 cells were acquired and the analysis was determined by overlaying the histograms of the samples stained with the different reagents. Cells were then analyzed using a FACScan analyzer (Becton Dickinson) and data were processed by using Consort 30 Software programs (Becton Dickinson).
Culture conditions. Purified B-CLL leukemic cells were cultured in round-bottom 96-well plates (Tirtetek; ICN, Oxnard, CA) in RPMI 1640 medium supplemented with 10% FCS (ICN), penicillin (100 UlmL), and streptomycin (50 mglmL). Cultures were performed in triplicate, with each well containing 1 X 10% cells in 0.2 mL of medium and were incubated for 5 days at 37°C in a humidified atmosphere of 5% CO2 and 95% air. Cytokines were added at the beginning of the culture in different concentrations. TNFa was used at 20, 200, and 500 UlmL; IL-2 at IO, 100, and 500 U/mL; GM-CSF at IO, 100, and 500 ng/mL; G-CSF at IO, 100, and 500 U/mL; and L 3 at I , 10, and 100 UlmL. To investigate a cooperative effect of the above-mentioned cytokines on leukemic cells, different combinations of these molecules were used. Proliferation was determined by pulsing plates with 1 mCilwell of 'H-thymidine (CEA Ire Sorin, Saluggia, Italy) for the last 12 hours of culture; cells were then harvested and 'H-thymidine incorporation was measured in a p-scintillation counter.
Results are expressed as stimulation index (SI) according to the formula: mean cpm stimulated cellslmean cpm cultured cells in medium aIone; and as a percentage of inhibition according to the following formula: (1 -cpm in the presence of the stimulus and antibody/ cpm in the presence of the stimulus) X 100.
RESULTS

Expression and function of TNF-R and IL-2R on leukemic B cells. To investigate the relationship between TNF-R and IL-ZR, leukemic B cells were analyzed for the expression of the above-mentioned receptors after culture in medium
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From (Fig IB) subunit but not the 75-kD IL-2R (Fig IA) with respect to cells cultured in medium alone. On the contrary, IL-2 did not upregulate the expression of these receptors. The combination of both cytokines determined the same effect of TNFa alone. The binding assay of PE-IL-2 to leukemic cells showed an enhanced IL-2 binding (Fig IC) only when cells were cultured in the presence of TNFa or in the presence of the combination of TNFa and IL-2. This was documented by the shift to the right of the IL-2 histogram and by the block provided by cold IL-2 (data not shown). These findings indicate that the 55-kD IL-2R on leukemic B cells is upregulated by TNFa. When leukemic B cells were analyzed for the expression of TNF receptors, only the 75-kD TNF-R was detectable on neoplastic B lymphocytes cultured in medium alone, thus confirming data previously reported.3 After culture of leukemic B cells with IL-2, TNFa, or in the presence of both cytokines, we did not observe any modification in the expression of the two different TNF-R (Fig ID and E) . These observations were further confirmed by the demonstration of the lack of any modification in the binding of the PE-TNFa (Fig IF) .
To verify whether the upregulation of IL-2R leads to a functional difference in B-cell response to these two cytokines, leukemic B cells were cultured in the presence of TNFa and IL-2 both individually and in the presence of a combination of these two molecules. The results obtained are illustrated in Fig 2. Both cytokines (IL-2 and TNFa) displayed a low proliferative activity on these neoplastic cells when used individually (IL-2 10 U/mL, 1.7 t 0.5; IL-2 100 U/mL, 6.1 2 3.2; IL-2 1,000 U/mL, 20.2 2 5.6; TNFa 10 U/mL, 7.2 ? 4.7; TNFa 100 U/mL, 9.8 -+ 5.5; TNFa 500 U/mL, 8.4 ? 2.8). A synergistic effect was observed by the combination of both cytokines, thus validating the results obtained with flow cytometry analysis. On the other hand, we did not observe any synergistic effect when leukemic cells were preincubated with TNFa or IL-2 and successively cultured in the presence of IL-2 or TNFa. 
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Expression and function of hematopoietic growth factor receptors on leukemic B cells. Because other cytokines, including CSFs and, in particular, IL-3, have been reported to act as growth factors for normal B cells, we evaluated the role of hematopoietic growth factors and their receptors on leukemic B cells from B-CLL patients. Receptors for GM-CSF, G-CSF, and IL-3 were investigated by using PE-conjugated cytokines and antibodies that recognize the a chain of IL-3 and GM-CSF receptors. The analysis of CSF receptors on freshly isolated B cells from 2 patients with B-CLL and 2 normal subjects is reported in Fig 3. The histograms reported in Fig 3 show that freshly isolated leukemic B cells (Fig 3A and B) bind PE-conjugated IL-3, G-CSF, and GM-CSF, whereas normal B lymphocytes (Fig 3C and D) did not bind the above-mentioned reagents. Flow cytometry analysis of B cells using MoAbs that recognize the Q chain of IL-3 and GM-CSF receptors showed a slight but significant shift on freshly isolated leukemic B cells (Fig 4A and  B) but not on freshly isolated normal B lymphocytes (Fig  4C and D) . To address the issue of whether the binding of these PE-conjugated cytokines is related to the actual presence of CSF receptors rather than to an aspecific binding, blocking experiments with specific MoAbs were performed. Figure 5A shows that the binding of PE-IL-3 in one representative patient is shifted to the left when leukemic cells were preincubated with anti-IL-3R MoAb. A similar finding was observed when GM-CSF receptor is considered (Fig 5B) . In particular, the binding of PE-GM-CSF is shifted to the left when leukemic cells were preincubated with a mixture of two MoAbs against GM-CSF receptor. Because TNF-R and IL-2R are constitutively expressed on leukemic B cells from CLL patients and not on normal B lymphocytes, we investigated whether these cytokines (IL-2 and TNFa) regulate the expression of IL-3, G-CSF, and GM-CSF receptors and whether they induce proliferation in different combinations.
The analysis of cells cultured in different experimental conditions showed that the above-quoted receptors are constitutively expressed on neoplastic B cells cultured in medium alone (Fig 6 shows the data obtained in 1 representative patient). All these receptors were upregulated by the in vitro culture of leukemic cells in the presence of IL-2. This finding was consistently observed in other patients studied and is detectable at almost 100 and 1,OOO U/mL IL-2 concentrations, whereas the 10 U/mL IL-2 concentration did not affect the binding of PE-CSF on these cells. On the other hand, TNFa did not upregulate these receptors. In the representative patient shown in Fig 6, the histogram of G-CSF receptor was even shifted to the left with respect to control, indicating a downregulation of G-CSF receptor expression; this finding was observed in 2 of 12 patients studied and its meaning is, at present, elusive.
To verify whether the 55-kD IL3R is involved in the mechanism leading to the upregulation of CSFs receptors, leukemic B cells were cultured for 48 hours in the presence of anti-CD25 MoAb and IL-2, as well as in the presence of medium containing control MoAb or IL-2 alone. When the 55-kD IL-2R subunit was blocked with specific MoAb before in vitro stimulation with IL-2, we did not find any upregulation of G-CSF and IL-3 receptors as shown after culture of leukemic cells with IL-2 alone (Fig 7) , whereas a slight shift of the GM-CSF receptor histogram was observed. This indicates that CSF receptor upregulation is mediated via the 55-kD IL-2R.
Hematopoietic growth factors were assessed for their functional activity on leukemic B cells in a proliferative assay. The data reported in Fig 8 show the results (Fig 8A) , only GM-CSF exhibited a low proliferative activity on these cells in vitro at different concentrations (SI, 3.0 5 1.7, 2.9 t 1.1, and 5.6 2 3.4 at 10, 100, and 500 UlmL, respectively), whereas neither G-CSF nor IL-3 induced the growth of leukemic B cells. To assess the role of the combination of CSFs, IL-2, and TNFa on leukemic cell proliferation, grading concentrations of CSFs and fixed IL-2 or TNFa concentrations were used. Figure 8B and C shows the results of these experiments. Neither G-CSF nor IL-3 enhanced the proliferation induced by IL-2 and TNFa. Only GM-CSF was shown to increase the IL-2 (SI, 28.2 2 5.6, 32.0 +. 6.9, and 54.2 % 18.3 at 10, 100, and 500 UlmL GM-CSF concentrations, respectively) and TNFa (SI, 15.1 2 10.1, 22.2 5 16.0, and 14.0 2 6.4, at 10, 100, and 500 UlmL GM-CSF concentrations, respectively) mediated proliferation.
DISCUSSION
Data presented in this report show that the 55-kD IL-2R on leukemic B cells obtained from B-CLL patients is upregulated by TNFa and that the combination of IL-2 and TNFa exhibited a synergistic proliferative effect. Furthermore, evidence has been provided that leukemic B cells bear receptors for hematopoietic growth factors (GM-CSF, G-CSF, and EL-3) that may be upregulated by IL-2 via the 55-The evidence that TNFa is able to upregulate the expression of the 55-kD IL-2R indicates that these two receptorial structures (75-kD TNF-R and 55-kD IL-2R) are closely rekD IL-2R. Log. fluorescence intensity lated, similar to what is reported in the literature in terms of normal T cells in vitro.5" In fact, IL-2 enhanced the TNFR expression and TNFa increased the IL-2R expression, indicating that the functional effects shown by these cytokines are closely related. In our study, IL-2 poorly influenced or had no effect on TNF-R expression, whereas TNFa upregulated the expression of the 55-kD IL-2R. The partial shift of the 55-kD IL-2R histogram after TNFa stimulation might suggest that the receptor enhancement occurred in a subpopulation of CLL cells. The fact that IL-2 did not induce any modification of TNF receptors in our patients is not in agreement with the data reported by Digel et a1: who showed an upregulation of TNF receptors by IL-2. These discrepancies might be the consequence of different approaches in assessing the receptors on cell surface membrane. This finding indicates that TNFa, in terms of receptor expression, displays a more pronounced effect on leukemic B cells from these patients than does IL-2. Leukemic B lymphocytes obtained from B-CLL patients slightly proliferated to lL-2 and TNFa when used independently, but a high proliferative rate was commonly documented when both cytokines were combined. The proliferative rate displayed by the combination of these two cytokines on leukemic B cells is likely to be the consequence of a synergistic rather than a cumulative effect. In fact, the SI obtained after culture of leukemic cells in the presence of both TNFa and IL-2 increased 5 to 10 times with respect to the SI obtained after culture with TNFa alone and from 2 to 4 times as compared with the in vitro stimulation with IL-2. Whether this effect is discretely related to the upregulation of 55-kD IL-2R by TNFa remains unclear. At present, it is difficult to explain this synergistic proliferative effect entirely on the basis of the upregulation of the lowaffinity IL-2R, because the 55-kD IL-2R is not capable of mediating any signal transduction. Furthermore, we were unable to show the presence of the 75-kD IL-2R on these cells either when cultured in medium alone or with the combination of both cytokines. A third molecule, defined as the 64-kD IL-2R subunit, has been reported to display a regulatory function in the binding and avidity of L-2R for 1L-2.3"33 Until now, there has been no direct evidence that these cells bear the 64-M> IL-2R, but we can not rule out the presence of this molecule and its possible modulation. An alternative explanation for this synergistic effect might be indirectly related to the putative release of unknown cytokines.
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+ anti-55kDa IL-2R mAb Log. fluorescence intensity The evidence that the expression of CSF receptors can be upregulated after culture of leukemic B cells in the presence of IL-2 represents a new interesting observation, documenting another functional property of IL-2.
In other words, IL-2 not only delivers a proliferative signal to leukemic B lymphocytes from B-CLL patients but also provides other regulatory properties, ie, the upregulation of different cytokine receptors, including GM-CSF, G-CSF, and IL-3 recep-4255 tors. This new effect might play a role in the physiopathology of leukemic cells because IL-2 can display a functional role not only directly by inducing B-cell proliferation but also indirectly by modifying the expression of receptors, as observed here, or by regulating the production of other cytokines, as shown in other cell systems.x,9 Furthermore, the shift to the right of CSF receptor histograms induced by IL-2 is likely to be related to the increase of receptor expression or affinity rather than to the increased number of cells constitutively expressing the receptors. The fact that the upregulation of CSF receptors by IL-2 is inhibited by the blocking of the 55-kD IL-2R (Fig 4) indicates that the effect we observed is in fact mediated by IL-2 and specifically via the SS-kD TL-2R. These findings point out a new functional activity of these structures on leukemic B cells, which may ultimately take place in vivo in these patients.
The observations that leukemic B cells bear hematopoietic growth factors and that their expression is regulated by IL-2 represent new areas of investigation and discussion. The fact that GM-CSF, IL-3, and G-CSF receptors are constitutionally expressed on neoplastic B lymphocytes obtained from patients with B-CLL might suggest new pathogenetic views to explain the physiopathologic events leading to the decrease of other cell types in the peripheral blood of B-CLL patients. In particular, the in vivo binding of these cytokines to leukemic B cells might result in a starvation of these factors for the relevant targets, with a consequent depletion of neutrophils in these patients.
To investigate the role of CSF in leukemic growth, we performed in vitro proliferative assays with these cytokines. The evidence that neither G-CSF nor IL-3 induced leukemic cells to proliferate when used singularly or in association with IL-2 and TNFa, even though their receptors are upregulated by IL-2, indicates that these molecules do not behave as autocrine factors in this disorder. Because these receptors can be upregulated by IL-2 but do not transduce any proliferative signal, this upregulation in terms of functional properties remains to be clarified. Furthermore, only GM-CSF evokes a detectable proliferative response in B-CLL. This functional property, coupled to the demonstration of GM-CSF receptors on leukemic cells, might indicate that this molecule plays a functional role in leukemic cell growth in vitro and possibly in vivo.
